<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vestim</journal-id><journal-title-group><journal-title xml:lang="ru">Известия Национальной  академии наук Беларуси. Серия медицинских наук</journal-title><trans-title-group xml:lang="en"><trans-title>Proceedings of the National Academy of Sciences of Belarus, Medical series</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1814-6023</issn><issn pub-type="epub">2524-2350</issn><publisher><publisher-name>The Republican Unitary Enterprise Publishing House "Belaruskaya Navuka"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29235/1814-6023-2021-18-2-220-227</article-id><article-id custom-type="elpub" pub-id-type="custom">vestim-764</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКАЯ И ЭКСПЕРИМЕНТАЛЬНАЯ МЕДИЦИНА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL AND EXPERIMENTAL MEDICINE</subject></subj-group></article-categories><title-group><article-title>Противовоспалительные свойства комбинации мелоксикама и N-ацетилL-пролина</article-title><trans-title-group xml:lang="en"><trans-title>Anti-inflammatory properties of the combination of meloxicam and N-acetyl-L-proline</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Волчек</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vauchok</surname><given-names>A. U.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Волчек Александр Владимирович – канд. мед. наук, доцент</p><p>пр. Дзержинского, 83, 220116, г. Минск</p></bio><bio xml:lang="en"><p>Aliaksandr U. Vauchok – Ph. D. (Med.), Associate Professor</p><p>83, Dzerzhinski Ave., 220116, Minsk </p></bio><email xlink:type="simple">alexwolczek@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дубовик</surname><given-names>Б. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Dubovik</surname><given-names>B. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дубовик Борис Валентинович – д-р мед. наук, профессор</p><p>пр. Дзержинского, 83, 220116, г. Минск</p></bio><bio xml:lang="en"><p>Barys V. Dubovik – D. Sc. (Med.), Professor</p><p>83, Dzerzhinski Ave., 220116, Minsk </p></bio><email xlink:type="simple">dubovik@bsmu.by</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Белорусский государственный медицинский университет</institution></aff><aff xml:lang="en"><institution>Belarusian State Medical University</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>04</day><month>06</month><year>2021</year></pub-date><volume>18</volume><issue>2</issue><fpage>220</fpage><lpage>227</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Волчек А.В., Дубовик Б.В., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Волчек А.В., Дубовик Б.В.</copyright-holder><copyright-holder xml:lang="en">Vauchok A.U., Dubovik B.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://vestimed.belnauka.by/jour/article/view/764">https://vestimed.belnauka.by/jour/article/view/764</self-uri><abstract><p>На модели каррагенинового отека лапы у мышей изучены противовоспалительные свойства комбинации мелоксикама и атипичного противовоспалительного средства N-ацетил-L-пролина (Гроцепрол®) при внутрижелудочном введении. Рассчитанные методом регрессионного анализа среднеэффективные дозы N-ацетил-Lпролина и мелоксикама составили 414 и 2,85 мг/кг соответственно. При сочетанном применении этих соединений в соотношении 40:1 их активность существенно возросла, ED50 мелоксикама снизилась до 1 мг/кг, а аналогичный показатель N-ацетил-L-пролина составил 43 мг/кг. Такая же тенденция наблюдалась и при другом массовом соотношении данных компонентов – 20:1. Анализ фармакодинамики комбинации препаратов по методике T. Chou показал аддитивный тип их взаимодействия, характерный для соединений с различными молекулярными мишенями. Установлено, что комбинаторные сочетания N-ацетил-L-пролина и мелоксикама в массовых соотношениях 40:1 и 20:1 демонстрируют синергизм, что позволяет снижать дозы компонентов в 2,7–9,6 раза.Взаимное усиление противовоспалительной эффективности НПВС N-ацетил-L-пролина и мелоксикама при их сочетанном применении по сравнению с их использованием индивидуально позволяет уменьшить дозу каждого из компонентов композиции, что минимизирует побочные эффекты и токсические риски и обосновывает приемлемость практического применения этой синергичной комбинации.</p></abstract><trans-abstract xml:lang="en"><p>The anti-inflammatory properties of the combination of meloxicam and atypical NSAID N-acetyl-L-proline (Groceprol®) after intragastric administration in a model of carrageenan paw edema in mice were studied. The average effective dose of N-acetyl-L-proline calculated by the regression analysis method in this model was 414 mg/kg, and the average effective dose of meloxicam was 2.85 mg/kg. In the combination in a ratio of 40:1, the activity of the compounds increases significantly, the ED50 of meloxicam decreases to 1 mg/kg, a similar value of N-acetyl-L-proline becomes 43 mg/kg. The same trend was also observed with another mass ratio of components of 20:1. The analysis of the pharmacodynamics of the combination of drugs according to the T. Chou method showed an additive type of interaction, typical for compounds with different mechanisms of primary action. It was established that a combination of N-acetyl-L-proline and meloxicam in the weight ratios of 40:1 and 20:1 demonstrate synergism, allowing to reduce the dose of the components in 2.7–9.6 times as compared with the effect of the drugs individually.The results of the study are the experimental justification for the use of anti-inflammatory synergistic combination of N-acetyl-L-proline and meloxicam.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>N-ацетил-L-пролин</kwd><kwd>мелоксикам</kwd><kwd>нестероидное противовоспалительное средство</kwd><kwd>каррагениновое воспаление</kwd></kwd-group><kwd-group xml:lang="en"><kwd>N-acetyl-L-proline</kwd><kwd>meloxicam</kwd><kwd>non-steroidal anti-inflammatory drug</kwd><kwd>carrageenan induced paw edema</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Rainsford, K. D. Aspirin and related drugs / K. D. Rainsford. – London : Taylor and Francis, 2004. – 800 p.</mixed-citation><mixed-citation xml:lang="en">Rainsford K. D. Aspirin and related drugs. London, Taylor and Francis, 2004. 800 p.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">A proline-rich polypeptide complex (PRP) isolated from ovine colostrum. Modulation of H2O2 and cytokine induction in human leukocytes / A. Zabłocka [et al.] // Int. Immunopharmacol. – 2007. – Vol. 7, N 7. – P. 981–988. https://doi.org/10.1016/j.intimp.2007.02.012</mixed-citation><mixed-citation xml:lang="en">Zabłocka A., Janusz M., Macała J., Lisowski J. A proline-rich polypeptide complex (PRP) isolated from ovine colostrum. Modulation of H 2O2 and cytokine induction in human leukocytes. International Immunopharmacology, 2007, vol. 7, no. 7, pp. 981–988. https://doi.org/10.1016/j.intimp.2007.02.012</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Oxaceprol, an atypical inhibitor of inflammation and joint damage / M. Ionac [et al.] // Pharmacol. Res. – 1996. – Vol. 33, N 6. – P. 367–373. https://doi.org/10.1006/phrs.1996.0051</mixed-citation><mixed-citation xml:lang="en">Ionac M., Parnham M. J., Plauchithiu M., Brune K. Oxaceprol, an atypical inhibitor of inflammation and joint damage. Pharmacological Research, 1996, vol. 33, no. 6, pp. 367–373. https://doi.org/10.1006/phrs.1996.0051</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Parnham, M. J. Antirheumatic agents and leukocyte recruitment. New light on the mechanism of action of oxaceprol / M. J. Parnham // Biochem. Pharmacol. – 1999. – Vol. 58, N 2. – P. 209–215. https://doi.org/10.1016/s0006-2952(99)00056-8</mixed-citation><mixed-citation xml:lang="en">Parnham M. J. Antirheumatic agents and leukocyte recruitment. New light on the mechanism of action of oxaceprol. Biochemical Pharmacology, 1999, vol. 58, no. 2, pp. 209–215. https://doi.org/10.1016/s0006-2952(99)00056-8</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Effect of oxaceprol on the synthesis and degradation in vitro of proteoglycans and proteins by calf articular cartilage explants / H. Riera [et al.] // Rev. Rheum. Mal. Osteoartic. – 1990. – Vol. 57, N 7–8. – P. 579–583.</mixed-citation><mixed-citation xml:lang="en">Riera H., Barbara A., Aprile F., Maheu E., Mitrovic D. Effect of oxaceprol on the synthesis and degradation in vitro of proteoglycans and proteins by calf articular cartilage explants. Revue du rhumatisme et des maladies ostéo-articulaires, 1990, vol. 57, pp. 579–583.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Harris, A. Effects of oxaceprol on the microcirculation in ischemia/reperfusion injury / A. Harris, A. Schropp, K. Messmer // Eur. J. Med. Res. – 1998. – Vol. 3, N 4. – P. 182–188.</mixed-citation><mixed-citation xml:lang="en">Harris A., Schropp A., Messmer K. Effects of oxaceprol on the microcirculation in ischemia/reperfusion injury. European Journal of Medical Research, 1998, vol. 3, no. 4, pp. 182–188.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Бизунок, Н. А. Производные аминокислот – потенциальные модификаторы клеточной продукции оксидантов / Н. А. Бизунок // Рецепт. – 2006. – № 3. – С. 28–32.</mixed-citation><mixed-citation xml:lang="en">Bizunok N. A. Derivatives of amino acids – potential modifiers of cell production of oxidants. Retsept [Recipe], 2006, vol. 47, pp. 28–32 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Волчек, А. В. Влияние атипичного НПВС N-ацетил L-пролина на пирогеналовую лихорадку / А. В. Волчек, Б. В. Дубовик // Рецепт. – 2008. – № 2. – С. 49–54.</mixed-citation><mixed-citation xml:lang="en">Volchek A. V., Dubovik B. V. Effect of atypical NSAID N-acetyl L-proline on fever caused by pyrogenal. Retsept [Recipe], 2008, no. 2, pp. 49–54 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Оценка ульцерогенного потенциала Оцепрола – НПВС из класса производных пролина / А. В. Волчек [и др.] // Медико-социальная экология личности: состояние и перспективы : материалы междунар. конф., Минск, 4–5 апр. 2003 г. / oтв. ред. Е. Н. Смирнова. – Минск, 2003. – С. 143–144.</mixed-citation><mixed-citation xml:lang="en">Volchek A. V., Volynets B. A., Romanovskii D. I., Kuvaeva Z. I., Dubovik B. V. Evaluation of ulcerogenic potential of Oceprol NSAID from proline derivatives class. Mediko-sotsial’naya ekologiya lichnosti: sostoyanie i perspektivy: Materialy mezhdunarodnoi konferentsii (Minsk, 4–5 aprelya 2003 goda) [Medical and social ecology of personality: state and prospects: Materials of the international conference (Minsk, April 4–5, 2003)]. Minsk, 2003, pp. 143–144 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Волчек, А. В. Изыскание противовоспалительных агентов среди производных пролина / А. В. Волчек, М. Б. Бокова, Н. А. Бизунок // Тр. молод. ученых. Юбилейное издание : cб. науч. работ / под общ. ред. С. Л. Кабака. – Минск, 2001. – С. 37–39.</mixed-citation><mixed-citation xml:lang="en">Volchek A. V., Bokova M. B., Bizunok N. A. Search for anti-inflammatory agents among proline derivatives. Trudy molodykh uchenykh. Yubileinoe izdanie: sbornik nauchykh rabot [Proceedings of young scientists. Jubilee edition: collection of scientific works]. Minsk, 2001, pp. 37–39 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Myers, M. J. Molecular mechanism of action responsible for carrageenan-induced inflammatory response / M. J. Myers, C. M. Deaver, A. J. Lewandowski // Mol. Immunol. – 2019. – N 109. – P. 38–42. https://doi.org/10.1016/j.molimm.2019.02.020</mixed-citation><mixed-citation xml:lang="en">Myers M. J., Deaver C. M., Lewandowski A. J. Molecular mechanism of action responsible for carrageenan-induced inflammatory response. Molecular Immunology, 2019, vol. 109, pp. 38–42. https://doi.org/10.1016/j.molimm.2019.02.020</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Chou, T.-Ch. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies / T.-Ch. Chou // Pharmacol. Rev. – 2006. – Vol. 58, N 3. – P. 621–681. https://doi.org/10.1124/pr.58.3.10</mixed-citation><mixed-citation xml:lang="en">Chou T.-Ch. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological Reviews, 2006, vol. 58, no. 3, pp. 621–681. https://doi.org/10.1124/pr.58.3.10</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
